Capha Pharmaceuticals Inc.

Equities

FPSUF

CA13962W1086

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:51:43 2023-02-27 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2023	Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

April 29, 2020 at 10:29 am EDT

Capha Pharmaceuticals Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced net loss was CAD 86,632 compared to CAD 123,046 a year ago.

Latest news about Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	23-04-25	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Capha Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-30	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-28	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-29	CI
Capha Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-29	CI
Mill City Gold Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2018	18-11-28	CI
Capha Pharmaceuticals Inc. (OTCPK:FPSU.F) cancelled the acquisition of Blockagram Inc. from Matt Warren.	18-04-29	CI
Capha Pharmaceuticals Inc. announced that it has received CAD 0.62 million in funding	17-12-26	CI

Chart Capha Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Capha Pharmaceuticals Inc. is a Canada-based company. The Company is engaged in exploring various opportunities in the medical technology space.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CAPHA PHARMACEUTICALS INC.	-.--%	64
ELI LILLY AND COMPANY	+38.51%	728B
NOVO NORDISK A/S	+33.05%	603B
JOHNSON & JOHNSON	-6.23%	360B
MERCK & CO., INC.	+18.78%	332B
ABBVIE INC.	+1.35%	279B
ASTRAZENECA PLC	+16.00%	244B
NOVARTIS AG	+8.09%	207B
ROCHE HOLDING AG	-5.77%	205B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals